News/ News/ News/ Oncology/ R&D Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid Phil Taylor biosimilar, Henlius Biotech, Hong Kong, Oncology 0 Comment China’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong Share X Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid https://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/
